Barclays PLC Terns Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 94,902 shares of TERN stock, worth $550,431. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,902

Previous 94,902 -0.0%

Holding current value

$550,431

Previous $792,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$6.49 - $10.8 $652,504 - $1.09 Million	-100,540 Reduced 51.44%	94,902 $792,000
Q2 2024 Aug 14, 2024	SELL	$4.54 - $8.2 $239,993 - $433,468	-52,862 Reduced 21.29%	195,442 $1.33 Million
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $795,688 - $1.34 Million	163,722 Added 193.57%	248,304 $1.63 Million
Q4 2023 Feb 15, 2024	BUY	$3.37 - $6.86 $101,959 - $207,549	30,255 Added 55.69%	84,582 $548,000
Q3 2023 Nov 07, 2023	SELL	$4.7 - $8.55 $980,377 - $1.78 Million	-208,591 Reduced 79.34%	54,327 $274,000
Q2 2023 Aug 03, 2023	SELL	$7.35 - $13.29 $2 Million - $3.61 Million	-271,842 Reduced 50.83%	262,918 $2.3 Million
Q1 2023 May 04, 2023	BUY	$7.91 - $12.0 $142,546 - $216,252	18,021 Added 3.49%	534,760 $6.33 Million
Q4 2022 Feb 13, 2023	SELL	$4.62 - $10.18 $657,698 - $1.45 Million	-142,359 Reduced 21.6%	516,739 $5.26 Million
Q3 2022 Nov 03, 2022	BUY	$1.87 - $6.42 $1.21 Million - $4.15 Million	645,973 Added 4921.7%	659,098 $3.88 Million
Q2 2022 Aug 12, 2022	SELL	$1.5 - $3.0 $3,340 - $6,681	-2,227 Reduced 14.51%	13,125 $33,000
Q1 2022 May 16, 2022	BUY	$2.83 - $6.7 $43,446 - $102,858	15,352 New	15,352 $46,000

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $218M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account